




1078–5884/00The Benefits of Combined Anti-platelet Treatment in Carotid
Artery Stenting
F.M. McKevitt,1* M.S. Randall,1 T.J. Cleveland,2 P.A. Gaines,2 K.T. Tan2 and
G.S. Venables11Neurology Department, Royal Hallamshire Hospital, and 2Sheffield Vascular Institute, Northern General
Hospital, Sheffield Teaching Hospitals NHS Trust, Sheffield, UKObjective. To assess the benefits of a combined anti-platelet regime of aspirin and clopidogrel in carotid artery
stenting.
Methods. A randomised controlled trial was performed comparing aspirin and 24-h heparin with aspirin and clopidogrel for
patients undergoing carotid artery stenting. Outcome measures included 30-day bleeding and neurological complications
and 30-day stenosis rates.
Results. Bleeding complications (groin haematoma or excessive bleeding at the groin site) occurred in 17% of the heparin
and 9% of the clopidogrel group (pZ0.35; n.s). The neurological complication rate in the 24-h heparin group was 25%
compared to 0% in the clopidogrel group (pZ0.02). The 30-day 50–100% stenosis rates were 26% in the heparin group and
5% in the clopidogrel group (pZ0.10; n.s).
Conclusions. The dual anti-platelet regime has a significant impact on reducing adverse neurological outcomes without an
additional increase in bleeding complications. This study was terminated prematurely due to an unacceptable level of
complications in the heparin arm of the trial.Keywords: Carotid stenosis; Angioplasty and stenting; Anti-platelet drugs.Introduction
The benefits of combined anti-platelet treatment in
coronary artery stenting have been long established.1
Significant reductions in post procedure myocardial
infarction and stent thrombosis have been demon-
strated when patients are treated with dual anti-
platelet regimens rather than with aspirin alone or
aspirin and warfarin.2 More recently the advantages of
dual anti-platelet treatment commencing prior to
coronary intervention have also been demonstrated,
with a reduction in peri-procedural adverse events.3
There is as yet, however, no randomised controlled
trials to recommend dual anti-platelet regimes in
carotid artery stenting.
Before this study commenced patients under-
going carotid endovascular treatment at our centreing author. Dr Fiona McKevitt, Neurology Depart-
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0522+ 06 $35.00/0 q 2005 Elsevier Ltd. All rights reserwere treated with aspirin prior to the procedure
followed by systemic heparin for anti-coagulation at
the time of the procedure and for 24 h afterwards.
This was an accepted regime that concurred with
specified protocols derived from a randomised
controlled trial comparing endovascular treatment
with carotid endarterectomy.4 The emerging evi-
dence from the coronary stenting studies began to
make apparent however, the greater role that anti-
platelet drugs may have in preventing adverse
outcomes, a benefit that may also be applicable to
carotid artery stenting. We therefore decided to
investigate the benefits of a dual anti-platelet regime
in carotid stenting and a prospective, randomised,
un-blinded trial comparing aspirin and heparin with
aspirin and the thienopyridine anti-platelet agent
clopidogrel was performed at our institution. It was
intended that this be a pilot for a larger study
demonstrating equivalence between the two treat-
ments but the study was terminated prematurely by
the investigators due to an unacceptable level of
complications in the heparin arm of the trial.Eur J Vasc Endovasc Surg 29, 522–527 (2005)
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This was a prospective, randomised, un-blinded trial
performed at a single centre between March 2000 and
September 2002. Approval was obtained by the local
ethics committee and written consent obtained from
each patient.Objectives
The primary objective was to evaluate the safety of
clopidogrel and aspirin compared to 24-h heparin and
aspirin in patients undergoing carotid artery stenting.
The secondary objectives were to assess the neuro-
logical complications in the first 30 days following the
procedure and the 30-day stenosis rates of the treated
artery as measured by carotid duplex imaging.Randomisation
Prior to carotid stenting patients were randomly
allocated to a treatment regime. The method used to
implement the random allocation sequence was
numbered sealed envelopes. An independent statis-
tician prepared the sequence generation, which was
blinded to those enrolling patients and to those
performing the carotid intervention.Inclusion and exclusion criteria
Patients with high-grade carotid artery stenosis,
confirmed by angiography (R70% NASCET criteria5)
with planned treatment by carotid artery stenting,
were considered for enrolment. CT or MRI scans were
performed on all patients to exclude haemorrhagic
stroke or haemorrhagic transformation of an ischaemic
stroke.
Other exclusion criteria included pre-existing treat-
ment with clopidogrel; patients unable or unwilling to
give informed consent; patients with active bleeding
or at high-risk of bleeding, for example, diagnosed
peptic ulcer within the last 6 months; patients
scheduled for any form of surgery (other than the
study procedure) during or for 10 days after the study
period; uncontrolled hypertension O180/110 mmHg
despite optimal medication and contra-indications to
study drugs, for example history of clopidogrel
sensitivity.Carotid stent procedure
All procedures were performed by an interventional
radiologist (TJC, PAG). The carotid stenting technique
has evolved, over the time of this study period, to
include the use of a cerebral protection device. The
techniques employed have previously been described
in detail.6Study drug regimes
Patients prior to the procedure were already on single
anti-platelet therapy, aspirin (acetylsalicylic acid)
75 mg. Patients randomised to the heparin group
were administered intravenous unfractionated
heparin to achieve an activated partial thromboplastin
time (APTT) ratio of 1.5–2.5 for 24 h following the
procedure (nZ25). Patients randomised to the clopi-
dogrel group were given a loading dose of clopidogrel
300 mg 6–12 h before the procedure and again as
75 mg 2 h prior to the procedure. This was then
continued as 75 mg daily for 28 days following stent
placement (nZ25). All patients were anti-coagulated
with a bolus of 5000 units of heparin (1 mg/Kg) during
the procedure itself and maintained on aspirin
thereafter.Endpoints
All patients were assessed prior to treatment, at
discharge and at 30 days following the procedure by
an independent stroke neurologist who was unaware
of the treatment allocation.
Primary endpoint
All bleeding complications occurring within the first
30 days of the procedure. These included haemor-
rhagic stroke, gastro-intestinal bleeding, bleeding
from the catheter site resulting in prolonged hospital-
isation or the development of a groin haematoma.
Secondary endpoints
Thirty day neurological complication rates. All neurologi-
cal complication events were documented. Amaurosis
fugax was defined as monocular visual loss lasting less
than 24 h. Transient ischaemic attack (TIA) was
defined as a new neurological deficit lasting less than
24 h. Minor stroke was defined as a new neurological
deficit lasting more than 24 h but less than 7 days.
Major stroke was defined as a new neurological deficit
that persists more than 7 days. It was subdivided at 30
days post-event into non-disabling stroke, if theEur J Vasc Endovasc Surg Vol 29, May 2005





F. M. McKevitt et al.524Oxford modified handicap score was 0–2 or disabling
stroke, if the Oxford modified handicap score was
equal or greater than 3.7Age
Mean (GSD) 66 (G8) 67 (G10)
Range 53–83 53–81
Male sex 13 (54%) 14 (61%)
Cerebral protection device 15 (63%) 17 (74%)
Stent device
Wallstent 23 (96%) 100 (100%)
SMART 1 (4%) 0 (0%)Thirty day stenosis rates. Carotid Doppler ultrasono-
graphy was used to assess stenosis rates at 30 days
following treatment. The method used to calculate the
stenosis is the in-stent/CCA peak systolic velocity
ratio.Closure device used 23 (96%) 21 (91%)





Hypertension 16 (67%) 16 (70%)
Peripheral vascular disease 7 (29%) 5 (22%)
Diabetes 5 (21%) 3 (13%)
Smoker (current or previous) 18 (75%) 16 (70%)
Ischaemic heart disease 11 (46%) 8 (35%)
Atrial fibrillation 0 (0%) 0 (0%)
Hypercholesterolaemia* 23 (96%) 21 (91%)
* Total cholesterolO5.0 mmol/l.Data collection, study power and statistical methods
Information was prospectively recorded for each
patient. Demographic, clinical and procedural vari-
ables recorded included age, sex, presenting event,
vascular risk factors, type of stent, type of cerebral
protection device and type of closure device used.
Data from the CAVATAS study suggests that the
incidence of death and major stroke within 30 days of
the procedure is 10%.4 To show a benefit of 20% (with
power of 80%) in favour of the use of combination anti-
platelet therapy would require a sample size in the
region of 3000. This was an initial pilot safety study
using a sample size of 120 patients to show that
patients treated with the combination anti-platelet
therapy were not disadvantaged, i.e. there was no
major difference between the two groups in terms of
embolic events or haemorrhagic complications. Fol-
lowing completion of this study it was planned to
expand the study by recruiting other centres.
All data were analysed using the SPSSw software
package. Only patients undergoing the carotid stent-
ing procedure were analysed. Comparisons between
groups were made using either Chi-square test or
Fisher’s exact test if the assumptions were not fulfilled.





Amaurosis fugax 1 (4%) 0 (0%)
TIA 2 (8%) 0 (0%)
Minor stroke 0 (0%) 0 (0%)
Major non-disabling stroke 1 (4%) 0 (0%)
Major disabling stroke 2 (8%) 0 (0%)
Death 0 (0%) 1* (4%)
Groin complications 4 (17%) 2 (9%)
30 day stenosis rates
0–49% 17/23 (74%) 20/21 (95%)
40–69% 2/23 (9%) 0/21 (0%)
70–99% 0/23 (0%) 1/21 (5%)
100% 4/23 (17%) 0/21 (0%)
TIA, transient ischaemic attack.
* Non-neurological related.Results
It was initially planned to randomise 120 patients into
this study but following an interim analysis it was
decided to stop the trial earlier than planned. During
this period 50 patients had been randomised to
intravenous unfractionated heparin (nZ25) or clopi-
dogrel (nZ25). Three patients did not undergo carotid
artery stenting (heparinZ1, clopidogrelZ2) since,
they were found to have carotid artery occlusions
(nZ2) or a non-significant stenosis (nZ1) prior to
treatment and were, therefore, excluded from further
analysis. Patient baseline characteristics are detailed in
Table 1. All complications are listed in Table 2.Eur J Vasc Endovasc Surg Vol 29, May 2005Bleeding complications
There were no gastro-intestinal bleeding compli-
cations or haemorrhagic strokes. Groin complications
occurred in 17% (nZ4) of the heparin group and in 9%
(nZ2) of the clopidogrel group. These differences were
not statistically different (pZ0.35 95% CIK11 to 27%).
In the heparin group, the complications comprised
three small groin haematomas that did not delay
discharge (in one there was failure to deploy the
closure device and manual compression alone was
performed) and one groin haematoma that did delay
discharge by 24 h. In this later case, the APPTratio was
greater than 10.
In the clopidogrel group, the groin complications
consisted of one small groin haematoma that did not
Dual Anti-platelet Treatment for Carotid Stenting 525cause delay of discharge and one groin haematoma
that resulted in a prolonged discharge (by 4 days). In
this case, a closure device was not used and manual
compression alone was performed.Neurological complications
The neurological complication rate including all
amaurosis fugax, TIA and all stroke in the heparin
group was 25% (nZ6/24). The complications com-
prised amaurosis fugax (nZ1/24), TIA (nZ2/24),
major non-disabling stroke (nZ1/24) and major
disabling stroke (nZ2/24). All these neurological
events were ipsilateral to the treated artery. These
events occurred within 24 h (nZ4), within 48 h (nZ1)
and at 8 days (nZ1). In the clopidogrel group, the all
neurological complication rate was 0% (nZ0/23). This
difference was statistically different (pZ0.02, 95%CI 8–
42%). There was one death (clopidogrel treated group)
that was related to the insertion of a pacemaker and
not stroke related.Thirty-day stenosis rates
In the heparin arm the 50–69% stenosis rate was 9%
(nZ2/23), 0% (nZ0/23) had a 70–99% stenosis and
17% (nZ4/23) had a 100% occlusion. Three of these
total occlusions were associated with adverse neuro-
logical events. In the clopidogrel group, the 50–69%
stenosis rate was 0% (nZ0/20), 5% (nZ1/20) had a
70–99% stenosis and 0% (nZ0/20) had a 100%
occlusion. The difference between the two groups
was not statistically significant (pZ0.10).Loss of data
The reasons for loss of duplex data at 30 days included
death (one), stroke (one), and non-attendance (two).Discussion
This study demonstrates that a dual anti-platelet
regime instigated prior to carotid artery stenting has
a significant impact on reducing adverse neurological
outcomes without an additional increase in bleeding
complications. This was an un-blinded randomised
controlled trial with patients reviewed at discharge
and at 30 days by an independent stroke neurologist
who had no access to the treatment allocation at the
time of review. It is the first randomised trial to assess
the benefits of a dual anti-platelet regime in carotidartery stenting, however it was terminated early
following a review of the first 50 enrolled patients.
Though the numbers were relatively small (the results
therefore at risk of a type II error) there was a marked
difference in outcome measures between the two
groups. This finding in addition to data emerging
from coronary stenting trials, demonstrating the
significant advantage of dual anti-platelet therapy on
preventing adverse events,8–10 lead to the decision by
the investigators to terminate the study prematurely. It
is noted that this difference is less marked if the
outcome measure, death and all stroke (as usually
used in carotid intervention studies) is employed.
However, anti-platelet agents and heparin are admini-
strated during carotid artery stenting to protect
against possible thrombo-embolic complications. As
this includes transient ischaemic attack, as well stroke,
all ischaemic neurological complications were
included.
At the beginning of this trial there was no consensus
for peri-procedural anti-platelet or anti-thrombotic
regimes. Some centres were already using dual anti-
platelet regimes,11 some were using aspirin with
procedural heparin and heparin for 24 h following
the procedure,4 some were using both a dual anti-
platelet regime and procedural heparin plus heparin
for 24 h following the stenting procedure12 and some
were withholding all peri-procedural anti-platelets
until 3 days after the procedure.13 Strong evidence
from percutaneous coronary intervention studies was
beginning to make clear however, that dual anti-
platelet regimes may be beneficial.
Early coronary angioplasty studies first demon-
strated the benefits of aspirin in place of unfractio-
nated heparin with a 76% relatively risk reduction of
post procedure myocardial infarction seen in the anti-
platelet group.14 As coronary artery stenting replaced
primary angioplasty the benefits of using a thienopyr-
idine based dual anti-platelet regimen in place of
aspirin alone, or an aspirin and warfarin combination,
were soon confirmed by several randomised con-
trolled trials.1,2,15,16
These initial trials were performed using the
thienopyridine ticlopidine, and despite ticlopidine
having several known unwanted side effects, includ-
ing causing severe neutropenia in 1% of patients, and
potentially fatal thrombotic thrombocytopenic pur-
pura (TTP) in 0.2% of patients, benefit for its use was
shown. At the inception of our trial clopidogrel had
recently been developed as an alternative agent with
fewer side effects and with probable equal efficacy. The
benefits of aspirin and clopidogrel following coronary
stenting have since been demonstrated in several large
randomised trials assessing this combination withEur J Vasc Endovasc Surg Vol 29, May 2005
F. M. McKevitt et al.526aspirin and ticlopidine.8–10,17 Though dual anti-plate-
let therapy have been shown to be efficacious follow-
ing coronary interventions it does not automatically
follow however, that the same benefit will be derived
following carotid procedures. Glycoprotein IIb/IIIa
inhibitors have been shown to reduce ischaemic events
following coronary interventions,18 but has not
reduced neurological complications following carotid
interventions.19 In addition, there is concern that it is
also associated with increased rates of intracerebral
haemorrhage.20 The use of glycoprotein IIb/IIIa
inhibitors during carotid artery stenting therefore,
has actively been discouraged.
The need for higher levels of platelet inhibition with
stents may in part be explained by the higher and
prolonged degree of platelet activation seen in stented
vessels as opposed to angioplasty alone.21,22 Previous
studies on heparin use in coronary stenting have
demonstrated a significant increase in platelet acti-
vation but in addition the initial adhesion of platelets
to the stent surface is not prevented by heparin.
Platelet aggregation is allowed to occur and this may
furthermore explain the higher re-stenosis and com-
plication rates demonstrated in patients treated with
anti-coagulants.23 In this study acute total thrombosis
of the treated carotid artery and all neurological
complications were seen in the heparin group only
and were ipsilateral to the stented carotid artery.
One potential confounding factor in this study is the
concomitant use of cerebral protection devices. These
devices reduce thrombo-embolic complications at the
time of the carotid stenting procedure and have been
shown to reduce neurological complication rates.24
Cerebral protection was utilised in 63% of the heparin
group and 74% of the clopidogrel group. All neuro-
logical events occurred in the heparin group and so a
separate review of this group was performed to assess
if the use of cerebral protection devices had an impact
on adverse events. Though the difference was not
statistically significant (pZ0.35) the trend seen was
surprising. There was an 11% (nZ1/9) neurological
complication rate for procedures performed without a
cerebral protection device compared to 33% (nZ5/15)
for procedures performed with a cerebral protection
device. It is unlikely therefore, that the use of cerebral
protection devices accounts for the difference seen
between the two groups.
Stent endothelialisation is a slow process and is
known to take between 28 and 96 days to complete.25
During this time the exposed metallic stent continues
to act as a source of platelet activation. The prolonged
use of clopidogrel after the procedure in comparison to
a limited period of heparin use may partly explain theEur J Vasc Endovasc Surg Vol 29, May 2005difference in outcomes between the two groups, in
particular the complications that occurred after 24 h.
This study adds to the limited literature on the use
of dual anti-platelet therapy in carotid artery stenting
and supports evidence from other forms of endovas-
cular stenting that platelet activation plays a key role
in the pathogenesis of stent occlusion and embolic
complications. We recommend dual anti-platelet treat-
ment with aspirin and clopidogrel for all patients
undergoing carotid stenting particularly when a
cerebral protection device is employed. If stents take
at least 96 days to endothelialise however, further
work needs to be considered to investigate the
optimum length of time needed to give dual anti-
platelet therapy.Acknowledgements
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